The phrase "a clinically worthwhile" is correct and usable in written English.
It can be used when discussing the value or significance of a clinical intervention, treatment, or research finding in a medical context.
Example: "The study demonstrated that the new treatment is a clinically worthwhile option for patients with chronic pain."
Alternatives: "medically valuable" or "clinically significant".
Furthermore, given the higher absolute risk of depressive episodes (Judd et al. [2002]), lithium probably does protect against depression to a clinically worthwhile degree, similar to recurrent unipolar depression (Cipriani et al. [2006]).
The pain must be of sufficient intensity (greater than 2 out of 10 on a numerical pain scale) to permit a clinically worthwhile effect to be demonstrated.
We considered a 10% increase in response rate to be a clinically worthwhile effect to justify utilisation of non-monetary incentives when disseminating surveys.
NSE seems to be a clinically worthwhile serum tumour marker for monitoring seminoma patients, with a sensitivity and specificity of the same order as HCG.
Data from a previous study [ 4] indicate that 3 secs is likely to be approximately 15% of discharge values and we consider an effect of this size to be a clinically worthwhile.
First, the proportion of patients achieving 5% weight loss (5% responders, a value widely considered as a clinically worthwhile weight change) [ 10] and the mean 9-month change in weight will be calculated in each study arm.
With locoregionally applied IL-2 a modest but clinically worthwhile improvement was obtained in six out of 16 patients; remarkably these six all belonged to the group of seven patients that were treated with intratumoral IL-2.
A 20 percentage point difference in MUVD was chosen because in our judgement such a difference would be clinically worthwhile and the effects on CMD suggest that such a difference is plausible.
In this context of a higher rate of biopsy or monitoring, the clinically worthwhile difference was altered to a 15% difference (an odds ratio of 1.8) from 45% to 60%.
All of these considerations should be balanced against maximising the sample size to get a more reliable estimate of the treatment effect; examination of secondary end points (DeMets, 2006) and important, pre-specified subgroup analyses; and not missing an intervention with a moderate benefit, which is still clinically worthwhile.
However, a treatment that benefits only a subset of patients may still be clinically worthwhile.
